21-hydroxylase deficiency natural history, complications and prognosis

Revision as of 15:50, 26 August 2017 by Skazmi (talk | contribs)
Jump to navigation Jump to search

Congenital adrenal hyperplasia main page

21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 21-Hydroxylase Deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency natural history, complications and prognosis

CDC on 21-hydroxylase deficiency natural history, complications and prognosis

21-hydroxylase deficiency natural history, complications and prognosis in the news

Blogs on 21-hydroxylase deficiency natural history, complications and prognosis

Directions to Hospitals Treating 21-Hydroxylase Deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Mehrian Jafarizade, M.D [2]

Overview

If left untreated, patients with 21-hydroxylase deficiency may progress to develop complications. Common complications of 21-hydroxylase deficient congenital adrenal hyperplasia include short stature, adrenal crisis, infertility, and precocious puberty. The prognosis of 21-hydroxylase deficiency is generally good with treatment.

Natural History

If left untreated, patients with 21-hydroxylase deficiency may progress to develop complications. Androgen excess in childhood leads to pseudoprecocious puberty, accelerated childhood growth with premature epiphyseal fusion, which causes an overall short stature, and various metabolic abnormalities. Adults may also face fertility issues, both in classic and non-classic forms of 21-hydroxylase deficiency. Testicular adrenal rest tumors(nodular hyperplasia arising from cells that have many characteristics of adrenocortical cells and migrated with the testis during fetal development) may also occurr and patients with 21-hydroxylase deficiency require monitoring for these tumors. These tumors indicate poor disease control and are usually reversible with optimum treatment.

Complications

Common complications associated with 21-hydroxylase deficiency include:[1][2]

Prognosis

  • The prognosis of 21-hydroxylase deficiency is generally good with treatment.
  • A small percentage of children and adults with infancy or childhood onset 21 hydroxylase deficiency die of adrenal crisis, even after diagnosis and initiation of treatment.
  • When a person is well, missing a dose or even several doses, may not worsen the immediate symptoms. However, glucocorticoid needs are increased during illness and stress.
  • Missed doses during time of illness can lead (within hours) to hypotension, shock, and death.[1][2]

References

  1. 1.0 1.1 Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J. Clin. Endocrinol. Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.
  2. 2.0 2.1 van der Kamp HJ, Wit JM (2004). "Neonatal screening for congenital adrenal hyperplasia". Eur. J. Endocrinol. 151 Suppl 3: U71–5. PMID 15554889.